BRIEF published on 03/14/2025 at 17:50, 20 days ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
BRIEF published on 03/14/2025 at 17:50, 20 days ago PHAXIAM Therapeutics cherche repreneur en redressement judiciaire Euronext Paris Redressement Judiciaire PHAXIAM Therapeutics Recherche Repreneur Prolongation Procédure
PRESS RELEASE published on 03/14/2025 at 17:45, 20 days ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
PRESS RELEASE published on 03/14/2025 at 17:45, 20 days ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics lance un processus de recherche de repreneurs dans le cadre de son redressement judiciaire. Appel d'offres ouvert jusqu'au 11 avril 2025 Appel D'offres Redressement Judiciaire Repreneurs Procédure PHAXIAM Therapeutics
BRIEF published on 03/06/2025 at 18:01, 28 days ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
BRIEF published on 03/06/2025 at 18:01, 28 days ago PHAXIAM Therapeutics entre en redressement judiciaire et retarde ses résultats financiers Retard Des Résultats Financiers Administrateur Judiciaire Suspension Des Échanges Mise Sous Séquestre De PHAXIAM Défis Biotechnologiques
PRESS RELEASE published on 03/06/2025 at 17:56, 28 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
PRESS RELEASE published on 03/06/2025 at 17:56, 28 days ago Informations privilégiées / Autres communiqués PHAXIAM annonce l'ouverture d'une procédure de redressement judiciaire et le report de la publication de ses résultats financiers 2024. La Société se place sous la protection du Tribunal de commerce de Lyon Résultats Financiers Tribunal De Commerce Redressement Judiciaire PHAXIAM Procédure
BRIEF published on 03/06/2025 at 11:45, 28 days 6 hours ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 03/06/2025 at 11:45, 28 days 6 hours ago Suspension de la Cotation de PHAXIAM Therapeutics Euronext Paris Biopharmaceutique Suspension Cotation PHAXIAM Therapeutics Infections Résistantes
Published on 04/03/2025 at 15:05, 3 hours 3 minutes ago Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 3 hours 8 minutes ago Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 3 hours 8 minutes ago UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 3 hours 8 minutes ago Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/03/2025 at 14:30, 3 hours 38 minutes ago Dominari Holdings Highlights Supporting American Companies
Published on 04/03/2025 at 17:45, 23 minutes ago Linedata Services: Linedata investit dans la finance de demain avec l’acquisition du spécialiste en IA NROAD
Published on 04/03/2025 at 17:45, 23 minutes ago Linedata Services: Linedata Invests in Future of Finance: Acquires AI Specialist NROAD
Published on 04/03/2025 at 17:45, 23 minutes ago BROADPEAK SA: Broadpeak publishes its annual results
Published on 04/03/2025 at 17:45, 23 minutes ago BROADPEAK SA: Broadpeak publie ses résultats annuels
Published on 04/03/2025 at 17:08, 59 minutes ago Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
Published on 04/03/2025 at 18:00, 8 minutes ago LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
Published on 04/03/2025 at 17:45, 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 04/03/2025 at 17:45, 23 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2025 at 17:45, 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
